  0 Table of Contents |
  1 Home |
| 2 Extensions |
| 3 Profiles |
| 4 Terminology |
 5 Artifacts Summary |
 5.1 Consumer (Onconova) |
| 5.2 Creator (Onconova) |
| 5.3 Onconova FHIR REST Server Capability Statement |
| 5.4 Adverse Event Profile |
| 5.5 Aneuploid Score Profile |
| 5.6 Cancer Family Member History Profile |
| 5.7 Cancer Patient Profile |
| 5.8 Cancer Risk Assessment Profile |
| 5.9 Cancer Stage Profile |
| 5.10 Comorbidities Profile |
| 5.11 ECOG Performance Status Profile |
| 5.12 Genomic Variant Profile |
| 5.13 Homologous Recombination Deficiency Profile |
| 5.14 Imaging Disease Status Profile |
| 5.15 Karnofsky Performance Status Profile |
| 5.16 Lifestyle Profile |
| 5.17 Loss of Heterozygosity Profile |
| 5.18 Lymphoma Stage |
| 5.19 Medication Administration Profile |
| 5.20 Microsatellite Instability Profile |
| 5.21 Molecular Tumor Board Review Profile |
| 5.22 Primary Cancer Condition Profile |
| 5.23 Radiotherapy Summary Profile |
| 5.24 Secondary Cancer Condition Profile |
| 5.25 Surgical Procedure Profile |
| 5.26 Therapy Line Profile |
| 5.27 TNM Distant Metastases Category Profile |
| 5.28 TNM Grade Category Profile |
| 5.29 TNM Lymphatic Invasion Category Profile |
| 5.30 TNM Perineural Invasion Category Profile |
| 5.31 TNM Primary Tumor Category Profile |
| 5.32 TNM Regional Nodes Category Profile |
| 5.33 TNM Residual Tumor Category Profile |
| 5.34 TNM Serum Tumor Marker Level Category Profile |
| 5.35 TNM Stage Group |
| 5.36 TNM Venous Invasion Category Profile |
| 5.37 Tumor Board Review Profile |
| 5.38 Tumor Marker Profile |
| 5.39 Tumor Mutational Burden Profile |
| 5.40 Tumor Neoantigen Burden Profile |
| 5.41 Vital Signs Panel Profile |
| 5.42 Adverse Event CTCAE Grade |
| 5.43 Adverse Event Mitigation |
| 5.44 Adverse Event Resolved Date |
| 5.45 Cancer Patient Age |
| 5.46 Cancer Patient Age at Diagnosis |
| 5.47 Cancer Patient Cause of Death |
| 5.48 Cancer Patient Clinical Center |
| 5.49 Cancer Patient Consent status |
| 5.50 Cancer Patient Data Completion Rate |
| 5.51 Cancer Patient Data Contributors |
| 5.52 Cancer Patient End of Records |
| 5.53 Cancer Patient Overall Survival |
| 5.54 Cancer Patient Vital status |
| 5.55 Cancer Stage Breslow Depth |
| 5.56 Family Member History Cancer Morphology |
| 5.57 Family Member History Cancer Topography |
| 5.58 Family Member History Condition Contributed to Death |
| 5.59 Genomic Variant Assessment Date |
| 5.60 Histological Differentiation |
| 5.61 Homologous Recombination Deficiency Interpretation |
| 5.62 Medication Administration Adjunctive Role |
| 5.63 Medication Administration Combined With |
| 5.64 Medication Administration Cycles |
| 5.65 Medication Administration Is Primary Therapy |
| 5.66 Molecular Tumor Board CUP Characterization |
| 5.67 Molecular Tumor Board Molecular Comparison |
| 5.68 Molecular Tumor Board Therapeutic Recommendation |
| 5.69 Primary Cancer Recurrence Of |
| 5.70 Primary Cancer Recurrence Type |
| 5.71 Risk Assessment Score |
| 5.72 Therapy Line Intent |
| 5.73 Therapy Line Number |
| 5.74 Therapy Line Progression Date |
| 5.75 Therapy Line Progression-Free Survival |
| 5.76 Therapy Line Reference |
| 5.77 Treatment Response RECIST Is Interpreted |
| 5.78 Tumor Board Specialization |
| 5.79 Tumor Marker Analyte |
| 5.80 Tumor Mutational Burden Status |
| 5.81 Adjunctive Therapy Roles Value Set |
| 5.82 Adverse Event Mitigation Categories Value Set |
| 5.83 Adverse Event Mitigation Drugs Value Set |
| 5.84 Adverse Event Mitigation Managements Value Set |
| 5.85 Adverse Event Mitigation Procedures Value Set |
| 5.86 Adverse Event Mitigation Treatment Adjustments Value Set |
| 5.87 Amino Acid Change Type Value Set |
| 5.88 Antineoplastic Agents Value Set |
| 5.89 Cancer Imaging Methods Value Set |
| 5.90 Cancer Risk Assessment Methods Value Set |
| 5.91 Cause of Death Value Set |
| 5.92 Clinical Relevance Value Set |
| 5.93 Coding DNA Change Types Value Set |
| 5.94 Comorbidity Panels Value Set |
| 5.95 Consent Status Value Set |
| 5.96 CTC Adverse Events Value Set |
| 5.97 Expected Drug Effects Value Set |
| 5.98 Exposure Agents Value Set |
| 5.99 Homologous Recombination Deficiency Interpretation Value Set |
| 5.100 ICD-10 Codes Value Set |
| 5.101 ICD-O-3 Differentiations Value Set |
| 5.102 ICD-O-3 Morphology Behavior Value Set |
| 5.103 ICD-O-3 Topographies Value Set |
| 5.104 Observation Body Sites Value Set |
| 5.105 Recreational Drugs Value Set |
| 5.106 Recurrence Types Value Set |
| 5.107 Risk Assessment Values Value Set |
| 5.108 Smoking status Value Set |
| 5.109 Surgical Procedures Value Set |
| 5.110 TNM Distant Metastasis Categories Value Set |
| 5.111 TNM Grade Categories Value Set |
| 5.112 TNM Grade Category Methods Value Set |
| 5.113 TNM Lymphatic Invasion Categories Value Set |
| 5.114 TNM Perineural Invasion Categories Value Set |
| 5.115 TNM Primary Tumor Categories Value Set |
| 5.116 TNM Regional Nodes Categories Value Set |
| 5.117 TNM Residual Tumor Categories Value Set |
| 5.118 TNM Serum Tumor Marker Level Categories Value Set |
| 5.119 TNM Venous Invasion Categories Value Set |
| 5.120 Treatment Intents Value Set |
| 5.121 Treatment Termination Reasons Value Set |
| 5.122 Tumor Board Recommendations Value Set |
| 5.123 Tumor Marker Analytes Value Set |
| 5.124 Tumor Marker Tests |
| 5.125 Tumor Mutational Burden Status Interpretation Value Set |
| 5.126 Vital Status Value Set |
| 5.127 Comorbidity Panels Code System |
| 5.128 Consent Status Code System |
 5.129 To Be Determined Codes |